Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Dirk Schriefer, Rocco Haase, Nils-Henning Ness & Tjalf Ziemssen. (2022) Cost of illness in multiple sclerosis by disease characteristics – A review of reviews. Expert Review of Pharmacoeconomics & Outcomes Research 22:2, pages 177-195.
Read now
Read now
Yoana Seitaridou, Ivo Tsekov, Maria Kamusheva, Maria Dimitrova & Guenka Petrova. (2022) Analysis of patients’ access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece. Expert Review of Pharmacoeconomics & Outcomes Research 22:2, pages 241-246.
Read now
Read now
Laurie J. Brown, Jinjing Li, Matthias Brunner, Martin Snoke & Hai A. La. (2021) Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression. Journal of Medical Economics 24:1, pages 140-149.
Read now
Read now
Emma van Eijndhoven, Michelle Brauer, Rebecca Kee, Joanna MacEwan, Lisa Mucha, Schiffon L. Wong, Adeline Durand & Jason Shafrin. (2020) Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis. Journal of Medical Economics 23:5, pages 474-483.
Read now
Read now
Timo Purmonen, Tanja Hakkarainen, Melina Tervomaa & Juhani Ruutiainen. (2020) Impact of multiple sclerosis phenotypes on burden of disease in Finland. Journal of Medical Economics 23:2, pages 156-165.
Read now
Read now
Peter Carney, Derek O’Boyle, Aidan Larkin, Christopher McGuigan & Killian O’Rourke. (2018) Societal costs of multiple sclerosis in Ireland. Journal of Medical Economics 21:5, pages 425-437.
Read now
Read now
Maarit E. Karhula, Anna-Liisa Salminen, Päivi I. Hämäläinen, Juhani Ruutiainen, Pertti Era & Asko Tolvanen. (2017) Psychometric evaluation of the Finnish version of the impact on participation and autonomy questionnaire in persons with multiple sclerosis. Scandinavian Journal of Occupational Therapy 24:6, pages 410-420.
Read now
Read now
Articles from other publishers (25)
Hasnat Ahmad, Julie A. Campbell, Ingrid van der Mei, Bruce V. Taylor, Qing Xia, Ting Zhao & Andrew J. Palmer. (2023) Estimating the disutility of relapse in relapsing–remitting and secondary progressive multiple sclerosis using the EQ-5D-5L, AQoL-8D, EQ-5D-5L-psychosocial, and SF-6D: implications for health economic evaluation models. Quality of Life Research 32:12, pages 3373-3387.
Crossref
Crossref
Izumi Kawachi, Hiromichi Otaka, Kosuke Iwasaki, Tomomi Takeshima & Kengo Ueda. (2022) Treatment Status and Healthcare Cost Trends for Patients with Multiple Sclerosis in Japan: A Claims Database Analysis. Neurology and Therapy 11:3, pages 1253-1268.
Crossref
Crossref
A Bouleau, C Dulong, CA Schwerer, R Delgrange, K Bouaou, T Brochu, S Zinai, K Švecová, MJ Sá, A Petropoulos, S Aly & P Labauge. (2022) The socioeconomic impact of multiple sclerosis in France: Results from the PETALS study. Multiple Sclerosis Journal - Experimental, Translational and Clinical 8:2, pages 205521732210932.
Crossref
Crossref
M. Michel, E. Le Page, D.A. Laplaud, R. Wardi, C. Lebrun, F. Zagnoli, S. Wiertlewski, M. Coustans, G. Edan, K. Chevreul, D. Veillard, F. Lallement, M. Cohen, C. Blanchard, E. Sartori, O. Demarco, F. Rouhart, C. Papeix, G. Taurin, T. Anani, P. Kassiotis, C. Hamon, M.A. Lester & M. Merienne. (2022) Cost-utility of oral methylprednisolone in the treatment of multiple sclerosis relapses: Results from the COPOUSEP trial. Revue Neurologique 178:3, pages 241-248.
Crossref
Crossref
Izumi Kawachi, Hiromichi Otaka, Kosuke Iwasaki, Tomomi Takeshima & Kengo Ueda. (2022) A Principal Component Analysis Approach to Estimate the Disability Status for Patients with Multiple Sclerosis Using Japanese Claims Data. Neurology and Therapy 11:1, pages 385-396.
Crossref
Crossref
Annukka Murtonen, Juho T. Lehto & Marja-Liisa Sumelahti. (2021) End of life in multiple sclerosis: Disability, causes and place of death among cases diagnosed from 1981 to 2010 in Pirkanmaa hospital district in Western Finland. Multiple Sclerosis and Related Disorders 54, pages 103139.
Crossref
Crossref
Nick Bansback*, Judy A Chiu*, Rebecca Metcalfe, Emmanuelle Lapointe, Alice Schabas, Marilyn Lenzen, Anthony Traboulsee, Larry D Lynd* & Robert Carruthers. (2021) Preliminary testing of a patient decision aid for patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical 7:3, pages 205521732110299.
Crossref
Crossref
Selin KALENDER & Vahit YİĞİT. (2021) Multipl Skleroz Hastalığının Engellilik Seviyesine Göre Maliyetleri: Sistematik Derleme ÇalışmasıCosts of Multiple Sclerosis According to the Level of Disability: A Systematic Review Study. Arşiv Kaynak Tarama Dergisi 30:2, pages 101-118.
Crossref
Crossref
Ran Zhou, Qiuming Zeng, Huan Yang, Yan Xu, Guojun Tan, Hongbo Liu, Lihua Wang, Hongyu Zhou, Meini Zhang, Jinzhou Feng, Tao Jin, Xinghu Zhang, Jiawei Wang, Xu Zhang, Feng Gao, Chunsheng Yang, Bitao Bu, Chunyang Li, Min Zhang, Huiqing Dong, Aiyu Lin, Weibin Liu, Lei Wu, Manxia Wang, Yulan Tang, Honghao Wang, Youming Long, Zhe Wang & Weihong Zheng. (2021) Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018. Frontiers in Neurology 12.
Crossref
Crossref
T. Heinonen, E. Castrén, T. Luukkaala, K. Mäkinen, J. Ruutiainen & H. Kuusisto. (2020) The retirement rate due to multiple sclerosis has decreased since 1995– A retrospective study in a Finnish central hospital. Multiple Sclerosis and Related Disorders 45, pages 102360.
Crossref
Crossref
Anna‐Leena Pirttisalo, Merja Soilu‐Hänninen, Marja‐Liisa Sumelahti, Olga Krökki, Annukka Murtonen, Katariina Hänninen & Jussi O. T. Sipilä. (2020) Changes in multiple sclerosis epidemiology in Finland over five decades. Acta Neurologica Scandinavica 142:3, pages 200-209.
Crossref
Crossref
Maria Paz-Zulueta, Paula Parás-Bravo, David Cantarero-Prieto, Carla Blázquez-Fernández & Agustín Oterino-Durán. (2020) A literature review of cost-of-illness studies on the economic burden of multiple sclerosis.. Multiple Sclerosis and Related Disorders 43, pages 102162.
Crossref
Crossref
Petri Mankinen, Tuomas Lundström, Erkki Soini, Marja-Liisa Sumelahti, Juhani Ruutiainen, Ulla Niskala & Elina Järvinen. (2019) Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis. Advances in Therapy 37:2, pages 800-818.
Crossref
Crossref
Stergios Tsiormpatzis. (2019) Effects of shiatsu on the health-related quality of life of a person with secondary progressive multiple sclerosis: A mixed methods N-of-1 trial within a whole systems research case study. European Journal of Integrative Medicine 32, pages 101006.
Crossref
Crossref
Renée Else Michels, Maria de Fransesco, Koshu Mahajan, Gerald J. D. Hengstman, Krijn M. H. Schiffers, Sangeeta Budhia, Gerard Harty & Marieke Krol. (2019) Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands. Applied Health Economics and Health Policy 17:6, pages 857-873.
Crossref
Crossref
Hanna Gyllensten, Andrius Kavaliunas, Chantelle Murley, Kristina Alexanderson, Jan Hillert, Petter Tinghög & Emilie Friberg. (2019) Costs of illness progression for different multiple sclerosis phenotypes: a population-based study in Sweden. Multiple Sclerosis Journal - Experimental, Translational and Clinical 5:2, pages 205521731985838.
Crossref
Crossref
Rafael Bolaños-Díaz, César Sanabria-Montañez & Nilton Custodio-Capuñay. (2019) Cost-effectiveness of interferon therapy for multiple sclerosis in Peru: impact of treatment adherence. Journal of Pharmaceutical Health Services Research 10:1, pages 125-132.
Crossref
Crossref
Hanna Gyllensten, Andrius Kavaliunas, Kristina Alexanderson, Jan Hillert, Petter Tinghög & Emilie Friberg. (2018) Costs and quality of life by disability among people with multiple sclerosis: a register-based study in Sweden. Multiple Sclerosis Journal - Experimental, Translational and Clinical 4:3, pages 205521731878335.
Crossref
Crossref
Hanna Gyllensten, Michael Wiberg, Kristina Alexanderson, Emilie Friberg, Jan Hillert & Petter Tinghög. (2017) Comparing costs of illness of multiple sclerosis in three different years: A population-based study. Multiple Sclerosis Journal 24:4, pages 520-528.
Crossref
Crossref
Hanna Gyllensten, Michael Wiberg, Kristina Alexanderson, Anders Norlund, Emilie Friberg, Jan Hillert, Olivia Ernstsson & Petter Tinghög. (2017) Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age. The European Journal of Health Economics 19:3, pages 435-446.
Crossref
Crossref
LARA GITTO. 2017. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis
17
37
.
Eija Rosti-Otajärvi, Päivi Hämäläinen, Anna Wiksten, Tanja Hakkarainen & Juhani Ruutiainen. (2017) Validity and reliability of the Fatigue Severity Scale in Finnish multiple sclerosis patients. Brain and Behavior 7:7, pages e00743.
Crossref
Crossref
Eija Rosti-Otajärvi, Päivi Hämäläinen, Anna Wiksten, Tanja Hakkarainen & Juhani Ruutiainen. (2017) Validity and reliability of the Finnish version of the Multiple Sclerosis Impact Scale-29. Brain and Behavior 7:7, pages e00725.
Crossref
Crossref
S. Skierlo, P. S. Rommer & U. K. Zettl. (2017) Symptomatic treatment in multiple sclerosis-interim analysis of a nationwide registry. Acta Neurologica Scandinavica 135:4, pages 394-399.
Crossref
Crossref
Erkki Soini, Jaana Joutseno & Marja-Liisa Sumelahti. (2017) Cost-utility of First-line Disease-modifying Treatments for Relapsing–Remitting Multiple Sclerosis. Clinical Therapeutics 39:3, pages 537-557.e10.
Crossref
Crossref